A phase II study of LY2510924, a novel cyclic peptide that blocks the binding of the ligand SDF-1 (CXCL12) to CXCR4 [16, 21], was conducted in patients with ED-SCLC who received LY2510924 plus carboplatin-etoposide (CE) versus CE alone (NCT01439568) [22]. The gene discussed is CXCL12; the disease is small cell lung carcinoma.